High Containment Manufacturing Capabilities for Highly Potent APIs

A Long History of Developing Hazardous Chemistries has Resulted in High Containment Capabilities

Occupational Health Categorization and Handling Practice Systems

- AFC's management of highly potent and potent compounds is effective in managing liability and productivity, remaining sensitive to people, ethics and compliance
- Systematic approach to classifying compounds and exposure situations when traditional tools (i.e., OELS, monitoring methods) are available
- Used to communicate risks and to establish consistent controls within the organization
- □ AFC has a Potent Compound Handling Program to ensure consistent handling
- AFC owns several isolated and independent facilities for highly potent compounds
- Potent compounds are safely handled at AFC via three broad areas of control:
 - Process design to minimize powder handling
 - Isolation of powders in properly designed facilities
 - Strict administrative controls and procedures

AFC uses 5 categories commonly used in the Pharmaceutical Industry

| Category 1: | Low toxicity | OEL > 1,000 mg/m ³ |
|-------------|----------------------|--|
| Category 2: | Intermediate Potency | OEL 100 µg/m ³ to 1,000 mg/m ³ |
| Category 3: | Highly Potent | OEL 5 to 100 μg/m ³ |
| Category 4: | Very Highly potent | OEL 0.5 to 5 µg/m ³ |
| Category 5: | Extremely potent | OEL < 0.5 μg/m ³ |

Compounds in Categories 3, 4, and 5 are considered "Highly Potent" They can include cytotoxic, carcinogenic, mutagenic, and teratogenic compounds

AFC Approaches HPAPI Manufacturing with 3 levels of Controls in Multiple Facilities


Level 1: Process Design


- Overall goal to avoid exposure of product to FOD and to avoid exposure of room and personnel to product
- Minimize isolation and handling dry powders through process optimization wherever possible
 - Telescope steps
 - Keep in solution Avoid isolation
 - Filter but do not dry or package intermediates
- Maximize batch sizes within cGMP
 - Size equipment appropriately
 - Multiple size equipment available

Level 2: Engineering

- Advanced Engineering Controls to Minimize Exposures
 - Process containment (barriers, isolation, etc.)
 - Closed Filter/dryer units
 - Reactor Charging Devices to eliminate open charge
 - Dryer/centrifuges discharge dust control devices
 - Closed mills (air locked feed and ventilated discharge)
 - Glove Boxes, cabinets
 - Closed transfer systems
 - Ventilated enclosures
 - Continuous liners for packaging from centrifuges and dryers







cGMP Facilities

Building 05017 – **0.2 μg/m**³ • 50 to 200 gal G/L reactors Hydrogenation





Building 05046 $-0.2 \ \mu g/m^3$ • 50 to 200 gal G/L reactors • Filter Dryer

Building 05111 $-0.2 \,\mu g/m^3$ • 50 liter - 20 gal G/L reactors • SMB unit (75 mm) • Filter Dryer HPAPI Milling



Level 3: Procedures

- Detailed Specialized Operating Instructions (MBR)
- Appropriate Hazard Communications
 - Process Training and Exhaustive PHA's
 - SDS + safety summaries
- Appropriate IH Monitoring to Verify Level of Containment
- Enhanced Medical Surveillance



- **Proper Personal Protective Equipment**
 - Protects against equipment or procedure failure

Charging Devices eliminate opening the manway

- Facility Design Elements
 - Negative differential air pressure in processing rooms relative to surrounding areas
 - Air locks/ante rooms provide air pressurization and serve as gowning/de-gowning area
 - Single pass HEPA-filtered room air
 - Controlled access to potent manufacturing areas
 - Products manufactured in stages in different facilities depending on potency of compound
 - Manufacturing of potent compounds requires adequate toxicity data and desensitization techniques



Building S3-Bay 31 (Virginia) – 0.2 μ g/m³ • 25 to 100 gal G/L & Hastelloy[™] reactors • Filter Dryer

Building S3-Labs (Virginia) - 5 ng/m³ 100 L Glass reactor 100 L Hastelloy[™] reactor Lab Scale equipment



AFC Equipment – Offers an Enabling Range of Capabilities

AFC can handle a Broad Spectrum of HPAPIs

| Category | Characteristics | Examples (OEL mcg/m³) | Location |
|----------|---|--|--|
| 1 | Relatively non-toxic or slightly toxic materials producing few systemic effects. Clinical doses above 500 mg/day. OEL: above 1000 mcg/m ³ LD ₅₀ : Greater Than 5000 mg/kg | | Plant 1 CS Area AFC-TX AFC-VA |
| 2 | Low Pharmaceutical potency producing very mild systemic toxicity, including mild sensitization reactions. Clinical doses of 20 - 500 mg/day. OEL: 100 - 1000 mcg/m³ LD ₅₀ : 500 - 5000 mg/kg | ACC-242 (100) ACC-311 (100) ACC-289 (200) ACC-282 | Plant 1 CS Area AFC-TX AFC-VA |
| 3 | Default category for unknown toxicity materials. Effects of overexposure are not life threatening or incapacitating. | ACC-234.2 (20) ACC-234.3 (120) | CS Area 05-148 |

Closed & Protected Charging/Discharging



Unique QC Analytical Capability


Dedicated facility for the preparation of HPAPI samples


- Scales within glove boxes for sample weight and dilution
- Room dedicated for analytical sample preparation only

Unique HPAPI Milling Capabilities

Blending Drum







Charging with double butterfly valves Enclosed discharge of product HEPA filters Air lock for gowning/de-gowning

Sample pass-through

Separate disposable chutes for solids and liquids within each hood

Negative differential air pressure in processing rooms relative to surrounding areas



HEPA Filtered, fully Contained Milling Suite

